All In Biotech

Drug Trial Radar · NCT06462586

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lumateperone in the Acute Treatment of Patients With Manic Episodes or Manic Episodes With Mixed Features Associated With Bipolar I Disorder (Bipolar Mania)

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

354

Actual

Start

Jun 19, 2024

Primary completion

Feb 24, 2026

Study completion Mar 5, 2026

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Conditions

  • Bipolar Disorder, Manic

Interventions

  • LumateperoneDrug

    Lumateperone 42 mg capsules administered orally, once daily

  • PlaceboDrug

    Matching capsules administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Young Mania Rating Scale (YMRS)Time frame: Week 3

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Rogers, Arkansas

  • Clinical Site

    Bellflower, California

  • Clinical Site

    Culver City, California

  • Clinical Site

    Garden Grove, California

  • Clinical Site

    Lemon Grove, California

  • Clinical Site

    Montclair, California

  • Clinical Site

    Hallandale, Florida

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami Gardens, Florida

  • Clinical Site

    Miami Lakes, Florida

  • Clinical Site

    Miami Springs, Florida

  • Clinical Site

    Orlando, Florida

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Atlanta, Georgia

  • Clinical Site

    Decatur, Georgia

  • Clinical Site

    Savannah, Georgia

  • Clinical Site

    Shreveport, Louisiana

  • Clinical Site

    Marlton, New Jersey

  • Clinical Site

    North Canton, Ohio

  • Clinical Site

    Austin, Texas

  • Clinical Site

    Austin, Texas

  • Clinical Site

    DeSoto, Texas

  • Clinical Site

    Lovech, Bulgaria

  • Clinical Site

    Rousse, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Stara Zagora, Bulgaria

  • Clinical Site

    Veliko Tarnovo, Bulgaria

  • Clinical Site

    Vratsa, Bulgaria

  • Clinical Site

    Split, Croatia

  • Clinical Site

    Zagreb, Croatia

  • Clinical Site

    Zagreb, Croatia

  • Clinical Site

    Guwahati, Assam, India

  • Clinical Site

    Mangalore, Karnataka, India

  • Clinical Site

    Mysore, Karnataka, India

  • Clinical Site

    Nashik, Maharashtra, India

  • Clinical Site

    Ludhiana, Punjab, India

  • Clinical Site

    Belgrade, Serbia

  • Clinical Site

    Kovin, Serbia

  • Clinical Site

    Kragujevac, Serbia

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.